Trump Eyeing To Promote Another Unproven Coronavirus ‘Cure,’ This Time An Experimental Extract

President Donald Trump has long promoted the use of anti-malarial drug hydroxychloroquine for the treatment and prevention of COVID-19, despite no medical proof available to back his claim. Now it is being said that POTUS is eyeing yet another unproven coronavirus “cure,” this time an experimental extract.

The president is expected to promote the extract “Oleandrin” on the recommendations of Housing and Urban Development Sec. Ben Carson. According to reports, the botanical extract from the plan Olandrin was suggested as a potential cure to the president by Carson in July during a meeting at the Oval Office.

The experimental extract has also been touted by MyPillow founder and CEO Mike Lindell, who is already known to be well-connected to Trump. The extract is being developed by pharmaceutical company Phoenix Biotechnology and Lindell is believed to hold stakes in it.

Lindell told a media outlet that Trump is considering the extract and even said that the U.S. Food and Drug Administration (FDA) should be approving it as a potential treatment for COVID-19.

Phoenix Biotechnology’s Andrew Whitney is also known to have met the president personally in July to discuss the effects of the botanical extract on coronavirus.

In a separate interview, Whitney claimed that the Oleandrin extract cured coronavirus disease within two days and that he is actively trying to make the extract available for public use. He said that he is open to making it available as a supplement, if not as a COVID-19 cure, as long as it is able to hit the shelves.

"Now, there are all sorts of lawyers who would tell me I can't say things like that, because you know you need to have years of studies, and you need to have this, that, and the other, and so forth," Whitney said during the interview. "But as an American with a right of free expression, I'm telling you, I've seen it with my own eyes."

He also clarified that by “cure” he means that most of the symptoms go away quickly in a majority of the patients. While a source said that no proof has been provided by Whitney to back his claim, he has a different story to tell.

Whitney says that they have already provided the proof to the FDA. When asked about evidence in humans, he said that the data is compelling and it best is left at that.

"We have something that we believe will address the problem and we want to make it available," he said. "We believe we should be given the opportunity to demonstrate that in a hospital clinical trial setting and we believe that must happen now and not a month from now."